A Study of SH006 Injection Combination Therapy in Patients With Advanced Solid Tumors

NCT07362264 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Liver Cancer

Interventions

DRUG: SH006

Sponsor

Nanjing Sanhome Pharmaceutical, Co., Ltd.